Project Grant R01HL184469
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $776K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $248,919 in a Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on June 1, 2026, to investigate skeletal muscle metabolism and exercise intolerance in heart failure patients with preserved ejection fraction (HFPEF). The award funds research using phosphorus magnetic resonance spectroscopy and magnetic resonance imaging to simultaneously measure muscle metabolism and peripheral blood flow in HFPEF...
- The National Heart, Lung, and Blood Institute awarded the University of Maryland, Baltimore $775,687 under Project Grant R01HL183332 on August 10, 2026, to support research on molecular drivers of pulmonary vascular remodeling in pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFPEF). The research investigates beta-2 microglobulin (B2M) as a therapeutic target in PH-HFPEF. The project builds on findings that PH-HFPEF patients display elevated circulating B2M...
- The National Heart, Lung, and Blood Institute awarded Brown University $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of chitinase 3-like-1 in pulmonary arterial hypertension pathogenesis. The project grant funds research into how the protein CHI3L1 contributes to immune and metabolic dysfunction underlying vascular remodeling in PAH, with particular focus on macrophage metabolism and pro-remodeling effects. The research...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $264,750 on July 1, 2026, for a Project Grant (R03HL178552) under the Cardiovascular Diseases Research program (CFDA 93.837) to identify pathogenic somatic mutations in pulmonary arterial hypertension. The award funds research to determine whether somatic (acquired) mutations in disease-causing pathways contribute to PAH pathogenesis. The work proceeds through two approaches: analyzing cell-free DNA in circulating...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $765,811 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate fatty acid oxidation and myosteatosis in peripheral artery disease. The research project examines the role of fatty acid oxidation in limb tissue mitochondria as a cause of myosteatosis and chronic limb-threatening ischemia presentations, and explores it as a site for interventional therapies. The...
- The National Heart, Lung, and Blood Institute (NHLBI), a component of the Department of Health and Human Services National Institutes of Health, awarded The Johns Hopkins University $248,999 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate reduced hypusination of EIF5A as a mechanism of heart failure with preserved ejection fraction (HFPEF). The research addresses mechanisms underlying HFPEF, which affects over half of heart failure patients but...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $874,973 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized, placebo-controlled clinical trial of carnitine supplementation in pulmonary arterial hypertension (PAH) patients. The trial enrolls PAH patients across the United States via remote enrollment over a 12-week study period with quality-of-life improvement as the primary endpoint and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Medical University of South Carolina $188,568 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 1, 2026, to investigate skeletal muscle microvascular dysfunction in systolic heart failure. The award funds research comparing pre- and post-exercise assessments of noninvasive measures of skeletal muscle microvascular function in the distal leg alongside invasive hemodynamic monitoring to...